Overview

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-03-20
Target enrollment:
Participant gender:
Summary
This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical